Botulinum Toxin A Use in the Gastrointestinal Tract: A Reappraisal After Three Decades

• Published in: Gastroenterology & hepatology Vol. 19; no. 4; pp. 198 - 212
• Main Authors: Mohajir, Wasay A, Khurana, Shruti, Singh, Khushboo, Chong, Reubyn William, Bhutani, Manoop S
• Format: Journal Article
• Language: English
• Published: Millennium Medical Publishing 01-04-2023
• Subjects: Column
• ISSN: 1554-7914

The discovery of botulinum toxin A (BTX)’s therapeutic properties has led to studies evaluating its usefulness in multiple medical disorders. Its use in the gastrointestinal (GI) tract has been studied for 30 years. Multiple databases, including PubMed, AccessMedicine, ClinicalKey, Cochrane Library, Embase, and Medline, were used to review research from case series to randomized controlled trials on BTX use in the GI tract. This article reviews the current literature on the efficacy of BTX and the strength of recommendations for or against its use in various disorders, including cricopharyngeal dysphagia, achalasia, nonachalasia motility disorders, gastroparesis, obesity, sphincter of Oddi disorders, chronic anal fissure, chronic idiopathic anal pain, and anismus. The appeal of BTX comes from its simplicity of administration, good safety profile, and reliability in decreasing muscular tone. However, there are several drawbacks that limit its use, including the lack of long-term efficacy and/or limited data in many GI disorders.